The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

Wednesday, June 16, 2021

Letter From the Editor - June


Hello JITC Readers,

This edition of the JITC Digest is extra special because June is Cancer Immunotherapy Month™. As JITC readers, you are already aware of the transformational impact of immunotherapy and we welcome you to take advantage of the myriad educational growth and professional development opportunities for clinicians, researchers, and patients offered by SITC during June.
 
June has already been a banner month for immunotherapy, especially for our clinical colleagues. Those of you who attended the American Society for Clinical Oncology Annual Meeting just a few weeks ago—or who followed JITC’s Twitter commentary—likely saw the panoply of oral abstracts, posters, plenary addresses, and education sessions all featuring impressive data showing benefit for a variety of immunotherapy approaches across numerous disease settings. If the results of RELATIVITY have you seeking more information on LAG3 or other targets, be sure to revisit JITC’s Immune Checkpoints Beyond PD-1 Series.
 
Of course, the clinical successes of immunotherapy stemmed from years of basic and translational research, more of which is needed to bring about the next generation of therapeutic agents to overcome resistance and expand the population of patients that may benefit. This month’s original research offers insight into mechanisms of resistance to a variety of immunotherapeutic modalities, with intriguing implications for future development.
 
Francisco J Cueto et al uncover paradoxical inhibition of Flt3L-mediated tumor clearance mediated by a surface receptor involved in cross-priming. Improved tumor control in mice with a novel, extended half-life recombinant IL-15 is demonstrated by Takahiro Miyazaki and colleagues. For the first time, hypoxia is shown to mediate anti-PD-1 resistance in head and neck cancer by Dan P Zandberg et al. Finally, Zhiliang Bai and colleagues identify functional differences in CAR T cells generated from healthy donors and patients.
 
After reading this month’s JITC, continue to celebrate Cancer Immunotherapy Month™ by supporting our sister journals in the immunotherapy space. You can find links to other specialized publications aiming to advance the field forward in this month’s special highlights section.
 
Best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

To view the entire April 2021 JITC Digest, please click here

No comments:

Post a Comment